Molecular targeted therapy of patients with non-small-cell lung cancer

被引：1

作者：

Stencel, Katarzyna ^{[1
,2
]}

Swiniuch, Daria ^{[1
,2
]}

Ramlau, Rodryg ^{[1
,2
]}

机构：

[1] Karol Marcinkowski Poznan Univ Med Sci, Chair & Dept Oncol, Poznan, Poland

[2] Poznan Univ Hosp Lords Transfigurat, Poznan, Poland

来源：

ONCOLOGY IN CLINICAL PRACTICE | 2019年 / 15卷 / 06期

关键词：

non-small-cell lung cancer; EGFR; ALK; ROS1; BRAF; targeted therapy; OPEN-LABEL; 1ST-LINE TREATMENT; EGFR MUTATIONS; CHEMOTHERAPY; AFATINIB; CRIZOTINIB; GEFITINIB; ADENOCARCINOMA; OSIMERTINIB; MULTICENTER;

D O I：

10.5603/OCP.2019.0025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer is the most common cause of cancer-related death both in men and women in Poland and worldwide. Patients diagnosed with non-small-cell lung cancer (NSCLC) of non-squamous and not otherwise specified (NOS) histologies may benefit from targeted therapies, because these types of cancers most often harbor molecular disturbances such as activating EGFR gene mutations, rearrangements of ALK, ROS1 or NTRK genes and BRAF gene mutation. These disorders are a positive predictors of the response to treatment with tyrosine kinase inhibitors. The necessity of molecular tests in patients with advanced NSCLC to be performed prior to qualification for systemic chemotherapy should be emphasized and - in the case of positive results - the use of targeted therapy in the first line treatment.

引用

页码：289 / 296

页数：8

共 25 条

[1]

[Anonymous], ASCO 2018 ANN M

[2] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study [J].

Douillard, J-Y ;

Ostoros, G. ;

Cobo, M. ;

Ciuleanu, T. ;

McCormack, R. ;

Webster, A. ;

Milenkova, T. .

BRITISH JOURNAL OF CANCER, 2014, 110 (01) :55-62

[3] Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update [J].

Hanna, Nasser ;

Johnson, David ;

Temin, Sarah ;

Baker, Sherman, Jr. ;

Brahmer, Julie ;

Ellis, Peter M. ;

Giaccone, Giuseppe ;

Hesketh, Paul J. ;

Jaiyesimi, Ishmael ;

Leighl, Natasha B. ;

Riely, Gregory J. ;

Schiller, Joan H. ;

Schneider, Bryan J. ;

Smith, Thomas J. ;

Tashbar, Joan ;

Biermann, William A. ;

Masters, Gregory .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (30) :3484-+

[4] Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology [J].

Lindeman, Neal I. ;

Cagle, Philip T. ;

Aisner, Dara L. ;

Arcila, Maria E. ;

Beasley, Mary Beth ;

Bernicker, Eric H. ;

Colasacco, Carol ;

Dacic, Sanja ;

Hirsch, Fred R. ;

Kerr, Keith ;

Kwiatkowski, David J. ;

Ladanyi, Marc ;

Nowak, Jan A. ;

Sholl, Lynette ;

Temple-Smolkin, Robyn ;

Solomon, Benjamin ;

Souter, Lesley H. ;

Thunnissen, Erik ;

Tsao, Ming S. ;

Ventura, Christina B. ;

Wynes, Murry W. ;

Yatabe, Yasushi .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (03) :323-358

[5] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].

Maemondo, Makoto ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Sugawara, Shunichi ;

Oizumi, Satoshi ;

Isobe, Hiroshi ;

Gemma, Akihiko ;

Harada, Masao ;

Yoshizawa, Hirohisa ;

Kinoshita, Ichiro ;

Fujita, Yuka ;

Okinaga, Shoji ;

Hirano, Haruto ;

Yoshimori, Kozo ;

Harada, Toshiyuki ;

Ogura, Takashi ;

Ando, Masahiro ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Saijo, Yasuo ;

Hagiwara, Koichi ;

Morita, Satoshi ;

Nukiwa, Toshihiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388

[6] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer [J].

Mok, T. S. ;

Wu, Y. -L. ;

Ahn, M. -J. ;

Garassino, M. C. ;

Kim, H. R. ;

Ramalingam, S. S. ;

Shepherd, F. A. ;

He, Y. ;

Akamatsu, H. ;

Theelen, W. S. M. E. ;

Lee, C. K. ;

Sebastian, M. ;

Templeton, A. ;

Mann, H. ;

Marotti, M. ;

Ghiorghiu, S. ;

Papadimitrakopoulou, V. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :629-640

[7] Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations [J].

Mok, Tony S. ;

Cheng, Ying ;

Zhou, Xiangdong ;

Lee, Ki Hyeong ;

Nakagawa, Kazuhiko ;

Niho, Seiji ;

Lee, Min ;

Linke, Rolf ;

Rosell, Rafael ;

Corral, Jesus ;

Migliorino, Maria Rita ;

Pluzanski, Adam ;

Sbar, Eric I. ;

Wang, Tao ;

White, Jane Liang ;

Wu, Yi-Long .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) :2244-+

[8] Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].

Mok, Tony S. ;

Wu, Yi-Long ;

Thongprasert, Sumitra ;

Yang, Chih-Hsin ;

Chu, Da-Tong ;

Saijo, Nagahiro ;

Sunpaweravong, Patrapim ;

Han, Baohui ;

Margono, Benjamin ;

Ichinose, Yukito ;

Nishiwaki, Yutaka ;

Ohe, Yuichiro ;

Yang, Jin-Ji ;

Chewaskulyong, Busyamas ;

Jiang, Haiyi ;

Duffield, Emma L. ;

Watkins, Claire L. ;

Armour, Alison A. ;

Fukuoka, Masahiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957

[9] Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study [J].

Novello, S. ;

Mazieres, J. ;

Oh, I-J. ;

de Castro, J. ;

Migliorino, M. R. ;

Helland, A. ;

Dziadziuszko, R. ;

Griesinger, F. ;

Kotb, A. ;

Zeaiter, A. ;

Cardona, A. ;

Balas, B. ;

Johannsdottir, H. K. ;

Das-Gupta, A. ;

Wolf, J. .

ANNALS OF ONCOLOGY, 2018, 29 (06) :1409-1416

[10] Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer [J].

Peters, Solange ;

Camidge, D. Ross ;

Shaw, Alice T. ;

Gadgeel, Shirish ;

Ahn, Jin S. ;

Kim, Dong-Wan ;

Ou, Sai-Hong I. ;

Perol, Maurice ;

Dziadziuszko, Rafal ;

Rosell, Rafael ;

Zeaiter, Ali ;

Mitry, Emmanuel ;

Golding, Sophie ;

Balas, Bogdana ;

Noe, Johannes ;

Morcos, Peter N. ;

Mok, Tony .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09) :829-838

← 1 2 3 →